1. Zhixia Yue,Chao Gao,Tianyu Xing,Wen Zhao,Chao Duan,Xisi Wang,Mei Jin,Yan Su*. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high‐risk neuroblastoma. PEDIATRIC BLOOD & CANCER.2023.70(5).1-10.SCI |
2. Zhi-Xia Yue,Tian-Yu Xing,Wen Zhao,Qian Zhao,Xi-Si Wang,Yan Su,Chao Gao,Shu-Guang Liu,Xiao-Li Ma*. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.Cancer Medicine.2022.11(8).1837-1849.SCI |
3. Zhi-Xia Yue,Tian-Yu Xing,Chao Gao,Shu-Guang Liu,Wen Zhao,Qian Zhao,Xi-Si Wang,Mei Jin,Xiao-Li Ma*. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification. Cancer Communications.2019.39(1).1-9.SCI |
4. Zhi-Xia Yue,Rui-qi Gao,Chao Gao,Shu-Guang Liu,Xiao-Xi Zhao,Tian-Yu Xing,Jing Niu*,Zhi-Gang Li,Hu-Yong Zheng,Wei Ding*. The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse.Cancer Cell International.2018.18:106.1-11.SCI |
5. Zhi‑Xia Yue,Cheng Huang,Chao Gao,Tian‑Yu Xing,Shu‑Guang Liu,Xing‑Jun Li,Qian Zhao,Xi‑Si Wang, Wen Zhao,Mei Jin,Xiao‑Li Ma*.MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.Cancer Cell International.2017.17:43.1-7.SCI |